17 results about "Serum neutralization" patented technology

The invention provides bovine ephemeral fever virus positive serum as well as a preparation method and application thereof. The preparation method comprises the following steps: culturing bovine ephemeral fever virus by using MDBK suspension cells, inactivating by using beta-propiolactone, concentrating by using a 500kd hollow fiber column to obtain an antigen solution, and emulsifying the antigen solution and 61VG adjuvant according to a mass ratio of 1: 1.5 to prepare the vaccine; carrying out primary immunization and secondary immunization on the receptor, collecting blood of which the serum neutralizing antibody titer is greater than 1: 4096 14-21 days after the secondary immunization, and separating to obtain positive serum. The positive serum can be used for specific test, identification test and the like of the bovine ephemeral fever virus, can also be used for preparing related reagents, kits and standard substances, and provides efficient and normative technical support for prevention and control of bovine ephemeral fever.

The invention belongs to the technical field of medicines, and discloses application of an adeno-associated virus vector in preparation of medicines for preventing and treating RSV infection and / or diseases caused by RSV. According to the invention, a recombinant adeno-associated virus vector is adopted for the first time to construct a medicine for preventing and treating RSV infection or diseases caused by RSV infection, and based on this, the invention provides a nucleic acid molecule which comprises: (a1) a first region which comprises a first adeno-associated virus inverted terminal repeat sequence, and (a2) a second region which comprises a second adeno-associated virus inverted terminal repeat sequence; and (a2) a second region comprising a gene encoding a respiratory syncytial virus antigen; the recombinant adeno-associated virus containing the nucleic acid molecule can generate better humoral immune effect and cellular immune effect, has a certain serum neutralization effect on strains of A and B subtypes of RSV, and particularly, when the antigen is a fusion protein of the respiratory syncytial virus or a fusion protein mutant of the respiratory syncytial virus, the recombinant adeno-associated virus has a certain serum neutralization effect on the strains of A and B subtypes of the RSV. The recombinant adenovirus vector containing the nucleic acid molecule can successfully realize the expression of the F protein before RSV fusion.

Provided herein are methods for reducing risk of severe symptoms and outcomes associated with Coronavirus Disease 2019 (COVID-19) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection by measuring levels of interleukin 6 (IL-6), IL-8, IL-22, and serum ferritin in a subject. Also provided are methods for treating a subject exposed to or at elevated risk of expose to SARS-CoV-2 based on levels of IL-6, IL-8, IL-22, and ferritin in the serum of the subject.

The invention relates to the technical field of in-vitro detection, in particular to a sample pretreatment method and a method for detecting VK2 and VD in serum. According to the specific technical scheme, the method comprises the following steps: carrying out protein precipitation after carrying out enzymolysis on serum, taking supernate, mixing the supernate with activated magnetic beads, enabling the magnetic beads to adsorb a target object, finally eluting the magnetic beads adsorbed with the target object by using eluent, collecting the eluent, and detecting the eluent to obtain vitamin K2 (VK2) and 25-hydroxy vitamin D (VD) at the same time. The problems that pretreatment operation is tedious, health is harmed and flux is low are solved by adopting an automatic magnetic bead method; the problems that detection equipment is expensive and difficult to popularize are solved by adapting to a conventional mass spectrum platform; the technical path is not only suitable for detection of vitamin K2 and 25-hydroxyvitamin D, but also provides a solution normal form with popularization value for detection of trace micromolecular markers which are difficult to popularize due to complex pretreatment or high equipment threshold.

A method for evaluating a capacity of a serum to neutralize a virus is disclosed. The method includes preparing a solution comprising at least one cell, a serum and a virus, placing the solution in contact with an organic electrochemical transistor comprising a source, a drain and a gate electrode, wherein the source and drain electrodes are electrically connected by means of a conductive channel, applying a potential difference between the drain and source electrode, applying a plurality of pulses of a potential difference between the gate and source electrode and measuring a respective plurality of values of pulses of current flowing through the channel; calculating a value of an estimation of a response time of the transistor, and comparing the value of the estimated response time with respect to a threshold value and detecting whether the serum has a neutralising capacity against the at least one virus.

The invention belongs to the technical field of in-vitro diagnosis, and discloses a kit for preliminary screening of ovarian cancer and application of the kit. The kit comprises a solid phase carrier and a tumor associated antigen coated on the solid phase carrier, wherein the tumor associated antigen is composed of ADHFE1, SAPCD2, ADAM17, REG4 and FLOT1. According to the kit, the five antigens ADHFE1, SAPCD2, ADAM17, REG4 and FLOT1 serve as a combination for screening the ovarian cancer for the first time, the content of ADHFE1, SAPCD2, ADAM17, REG4 and FLOT1 autoantibodies in serum can be specifically detected, high sensitivity and specificity are achieved, the detection success rate of ovarian cancer diseases is greatly increased, and wide application prospects are achieved.

The present application relates to the technical field of biological medicine, in particular to a kind of mRNA vaccine for obtaining bovine nodular skin disease virus neutralizing antibody and application thereof.The mRNA vaccine, characterized in that, contain A27L antigen selected fragment, or L1R antigen selected fragment.The mRNA vaccine provided by the present application successfully induced effective immune response in mice and cattle, detected high level of serum neutralization titer, and the effect is better than goatpox live vaccine (CVCC AV41) vaccine, and the antibody induced has no antibody-dependent enhancement effect.This breakthrough fills the blank in the current LSDV vaccine research and development field, provides a new solution for the production and research and development of animal vaccine, and has very high commercial value and broad application prospect.

The invention discloses a serum neutralization experiment automation system and method, and relates to the technical field of serum neutralization experiments. The system comprises a biological safety cabinet, an automatic operation module arranged in a closed operation space of the biological safety cabinet, and a control module in communication connection with the operation module, the automatic operation module comprises an XYZ mechanical arm unit, a pipetting unit mounted on the XYZ mechanical arm unit, a consumable bearing unit for placing experimental consumables and a reaction incubation unit for bearing and incubating a reaction container; the control module is configured to control the XYZ mechanical arm unit and the pipetting unit, and automatically complete the operations of taking and placing consumables from the consumable bearing unit, transferring liquid into the reaction container and transferring the reaction container between the consumable bearing unit and the reaction incubation unit. Through integrated full-automatic operation, the pathogen exposure risk of operators is remarkably reduced, manual errors are reduced, and the standardization degree, the result consistency and the data traceability of the experimental process are improved.

The invention discloses a preparation method and application of a novel hydrogel immunopotentiator, and belongs to the technical field of veterinary medicine. The preparation method comprises the following steps: adding a ferric trichloride solution into a hyaluronic acid solution, reacting in a stirring state, then adjusting the pH value to 5.5-7.5, and stirring to obtain hyaluronic acid hydrogel; 2 ', 3'-cGAMP with the final concentration of 0.1-800 g / mL is added into the hyaluronic acid hydrogel, and the hydrogel immunopotentiator is obtained. The invention also discloses an application of the hydrogel immunopotentiator in an alumina gel inactivated vaccine. The immunopotentiator disclosed by the invention has a 3D network structure, so that an agonist can be efficiently delivered to drainage lymph nodes in a targeted manner, systemic inflammatory reaction is avoided, and the immunopotentiation effect of the immunopotentiator is better exerted; when being used for the porcine epidemic diarrhea alumina gel inactivated vaccine, the porcine epidemic diarrhea alumina gel inactivated vaccine not only can obviously up-regulate the level of a serum neutralizing antibody, but also can effectively induce immune response of Th1 type cells and provide stronger immune protection response.

The invention provides an antibody combination and application thereof in a test strip for detecting IL-1Ra, IL-1beta and Brucella antibodies, and belongs to the technical field of cell factor and Brucella detection. The antibody combination provided by the invention comprises an IL-1beta paired antibody and an IL-1Ra paired antibody, the IL-1beta paired antibody comprises an IL-1beta-3-3 antibody and an IL-1beta-1S-4 antibody, and the IL-1beta paired antibody comprises an IL-1beta-3-3 antibody The IL-1Ra paired antibody comprises an IL-1Ra-2S-2 antibody and an IL-1Ra-1S-23 antibody, and the IL-1Ra paired antibody can be specifically combined with an IL-1beta recombinant protein, an IL-1Ra recombinant protein, and IL-1beta and IL-1Ra in natural sheep serum. The invention further provides a fluorescence immunochromatography test strip which can be used for qualitative and quantitative detection at the same time and can be used for detection of IL-1Ra, IL-1beta and Brucella antibodies in serum.

USE OF ADENO-ASSOCIATED VIRUS VECTOR IN PREPARATION OF MEDICAMENT FOR PREVENTING AND TREATING RSV INFECTION AND / OR RSV-INDUCED DISEASE For the first time, a recombinant adeno-associated virus vector is used to construct a medicament for preventing and treating RSV infection or a disease caused thereby. On this basis, a nucleic acid molecule is provided, comprising: (a1) a first region comprising a first adeno-associated virus inverted terminal repeat sequence, and (a2) a second region comprising a gene encoding a respiratory syncytial virus antigen. A recombinant adeno-associated virus comprising the nucleic acid molecule can produce a relatively good humoral immune effect and a relatively good cellular immune effect, and has a certain serum-neutralizing effect on both the subtype A strain and the subtype B strain of RSV. In particular, when the antigen is a fusion protein of the respiratory syncytial virus or a mutant of the fusion protein of the respiratory syncytial virus, the recombinant adenovirus vector comprising the nucleic acid molecule can successfully achieve the expression of the RSV pre-fusion F protein.

The application provides a foot-and-mouth disease virus broad-spectrum neutralizing antibody, a neutralizing antibody competition ELISA detection kit and application, and belongs to the technical field of antibodies. The foot-and-mouth disease virus broad-spectrum neutralizing antibody has an amino acid sequence of a heavy chain variable region as shown in SEQ ID NO:1 and an amino acid sequence of a light chain variable region as shown in SEQ ID NO:2. The application further provides a foot-and-mouth disease virus neutralizing antibody competition ELISA detection kit, which comprises the following components: a detection plate with a foot-and-mouth disease virus 146S antigen, a biotin-labeled foot-and-mouth disease virus broad-spectrum neutralizing antibody and an enzyme-labeled avidin. The detection sensitivity of the kit is 100%, the specificity is more than 99.5%, the negative / positive coincidence rate compared with the gold standard method VNT for detecting neutralizing antibodies is 92.8%, and the kit can more accurately reflect the level of neutralizing antibodies in serum.

This invention discloses a method for screening trace amounts of neutralizing antibodies against canine distemper virus (CDV). The method involves neutralizing the sample with live canine distemper virus, then inoculating it into Vero-Slam cells, using fluorescent lesions as the criterion. Detecting neutralizing antibodies using the true conformation of the virus ensures the highest degree of accuracy in detecting neutralizing antibodies. CDV-positive neutralizing serum (neutralizing titer 1:708) was serially diluted twofold to multiple concentration groups as the sample to be tested. The detection rate and limit of detection of CDV neutralizing activity of the method for each dilution of serum were determined. Results showed that serum with a CDV neutralizing titer of 1:708 diluted twofold... 12 The neutralizing activity after doubling is the lowest detection limit of the method of this invention, with a detection rate of 63.54 ± 4.774%. The method of this invention uses few reagents, none of which are expensive, resulting in low cost. This invention provides a new technical means for screening trace neutralizing antibodies against canine distemper virus.

The invention provides an equine arteritis virus bovine-derived serum neutralizing antibody as well as a preparation method and application thereof, and belongs to the technical field of veterinary biological products. And cattle is selected as an immune host, so that the bottleneck that a horse-derived antibody is difficult to obtain and high in cost is broken through. The highest titer of the equine arteritis virus neutralizing antibody prepared by using cattle as a host is 1: 128, the specificity is good, and the equine arteritis virus neutralizing antibody can fully meet the requirements on accuracy evaluation of an equine arteritis virus serum neutralizing test method, quality evaluation of an equine arteritis virus detection reagent and verification of laboratory equine arteritis virus detection capability; the problems of the traditional horse source antibody in the aspects of yield, titer and specificity are effectively solved.

A bioassay system for multiplexed detection and quantification of multiple analytes (e.g., Aβ40, Aβ42, pTau181, p217Tau, GFAP, and NFL) in a biological sample is provided. The bioassay system includes a plurality of sets of color-coded microspheres. Each set of microspheres is distinguishable by a unique color code generated by internal dyes. The bioassay system includes a first set of control microspheres attached to mouse polyclonal IgG to correct for a background of individual specimens and a second set of control microspheres configured to capture a synthetic peptide to normalize for well-to-well variations. Bioassay system also includes a fluidic system configured to mix the sample with the plurality of sets of color-coded microspheres to allow for specific binding between analytes and their corresponding capture agent among other analytes and a detection system for exciting and reading fluorescence of the internal dyes and a reporter fluorescence indicative of analyte binding.

The invention relates to the technical field of medicine, in particular to an inflammatory marker and virus antibody synchronous detection chip based on thermal annealing gold nanoparticles and application of the inflammatory marker and virus antibody synchronous detection chip. The invention provides a multiple detection chip for detecting CRP, SAA and tick-borne virus antibodies IgG / IgM in serum based on thermal annealing gold nanoparticles, the sample size demand is reduced in magnitude, the detection limitation of special crowds is broken through, the detection sensitivity is remarkably improved, and low-concentration target substances are accurately recognized. The method also has multiple detection capability, breaks through the limitation of single detection in the traditional technology, is excellent in clinical verification result, and ensures the detection reliability and practicability.

The invention belongs to the technical field of biological medicines, and particularly relates to a kit for detecting ovarian cancer and a detection method. The kit comprises an elisa plate and a tumor-associated antigen coated on the elisa plate, the tumor associated antigen is composed of a combination of Sui1, NDE1 and PDLIM1. According to the kit, the three antigens Sui1, NDE1 and PDLIM1 serve as a combination for screening the ovarian cancer for the first time, the content of the autoantibodies Sui1, NDE1 and PDLIM1 in serum can be specifically detected, high sensitivity and specificity are achieved, the detection success rate of ovarian cancer diseases is greatly increased, and wide application prospects are achieved.